Anebulo Pharmaceuticals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Anebulo Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 19.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 01 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2025 | N/A | -6 | N/A | N/A | 1 |
| 6/30/2024 | N/A | -8 | -8 | -8 | N/A |
| 3/31/2024 | N/A | -9 | -9 | -9 | N/A |
| 12/31/2023 | N/A | -10 | -10 | -10 | N/A |
| 9/30/2023 | N/A | -12 | -10 | -10 | N/A |
| 6/30/2023 | N/A | -12 | -10 | -10 | N/A |
| 3/31/2023 | N/A | -12 | -9 | -9 | N/A |
| 12/31/2022 | N/A | -11 | -8 | -8 | N/A |
| 9/30/2022 | N/A | -8 | -7 | -7 | N/A |
| 6/30/2022 | N/A | -7 | -5 | -5 | N/A |
| 3/31/2022 | N/A | -34 | -7 | -7 | N/A |
| 12/31/2021 | N/A | -41 | -6 | -6 | N/A |
| 9/30/2021 | N/A | -40 | -6 | -6 | N/A |
| 6/30/2021 | N/A | -38 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 214's forecast earnings growth is above the savings rate (0.8%).
Earnings vs Market: Insufficient data to determine if 214's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if 214's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 214's revenue is forecast to grow faster than the German market.
High Growth Revenue: 214 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 214's Return on Equity is forecast to be high in 3 years time